Boge Thierry, Rémigy Michel, Vaudaine Sarah, Tanguy Jérôme, Bourdet-Sicard Raphaëlle, van der Werf Sylvie
Centre Hospitalier de Bourg en Bresse, 01012 Bourg en Bresse, France.
Vaccine. 2009 Sep 18;27(41):5677-84. doi: 10.1016/j.vaccine.2009.06.094. Epub 2009 Jul 16.
Influenza vaccination is recommended for the elderly in many countries, but immune responses are weaker compared to younger adults.
To investigate the impact of daily consumption of a probiotic dairy drink on the immune response to influenza vaccination in an elderly population of healthy volunteers over 70 years of age.
Two randomised, multicentre, double-blind, controlled studies were conducted during two vaccination seasons in 2005-2006 (pilot) and 2006-2007 (confirmatory). Eighty-six and 222 elderly volunteers consumed either a fermented dairy drink, containing the probiotic strain Lactobacillus casei DN-114 001 and yoghurt ferments (Actimel, or a non-fermented control dairy product twice daily for a period of 7 weeks (pilot) or 13 weeks (confirmatory). Vaccination occurred after 4 weeks of product consumption. Geometric mean antibody titres (GMT) against the 3 viral strains composing the vaccine (H1N1, H3N2, and B) were measured at several time intervals post-vaccination by haemagglutination inhibition test.
In the pilot study, the influenza-specific antibody titres increased after vaccination, being consistently higher in the probiotic product group compared to the control group under product consumption. Similarly, in the confirmatory study, titres against the B strain increased significantly more in the probiotic group than in the control group at 3, 6 and 9 weeks post-vaccination under product consumption (p=0.020). Significant differences in seroconversion between the groups by intended to treat analysis were still found 5 months after vaccination. Similar GMT results were observed for the H3N2 strain and H1N1 strain, confirming the results of the pilot study.
These studies demonstrate that daily consumption of this particular probiotic product increased relevant specific antibody responses to influenza vaccination in individuals of over 70 years of age and may therefore provide a health benefit in this population.
许多国家建议老年人接种流感疫苗，但与年轻人相比，其免疫反应较弱。
研究每日饮用益生菌乳制品饮料对70岁以上健康老年志愿者群体流感疫苗免疫反应的影响。
在2005 - 2006年（试点）和2006 - 2007年（验证）两个疫苗接种季节进行了两项随机、多中心、双盲、对照研究。86名和222名老年志愿者分别每日饮用含有益生菌干酪乳杆菌DN - 114 001和酸奶发酵剂的发酵乳制品饮料（益力多），或一种非发酵对照乳制品，持续7周（试点）或13周（验证）。在饮用产品4周后进行疫苗接种。通过血凝抑制试验在接种疫苗后的几个时间间隔测量针对构成疫苗的3种病毒株（H1N1、H3N2和B）的几何平均抗体滴度（GMT）。
在试点研究中，接种疫苗后流感特异性抗体滴度升高，在饮用产品期间，益生菌产品组的抗体滴度始终高于对照组。同样，在验证研究中，在饮用产品的情况下，接种疫苗后3周、6周和9周，益生菌组针对B株的滴度显著高于对照组（p = 0.020）。通过意向性分析，两组之间的血清转化率在接种疫苗5个月后仍存在显著差异。对于H3N2株和H1N1株观察到类似的GMT结果，证实了试点研究的结果。
这些研究表明，每日饮用这种特定的益生菌产品可增强70岁以上个体对流感疫苗接种的相关特异性抗体反应，因此可能对该人群有益健康。
